Despite its prevalence, the molecular basis of squamous cell carcinoma (SCC) remains poorly understood. Here, we identify the developmental transcription factor Grhl3 as a potent tumor suppressor of SCC in mice, and demonstrate that targeting of Grhl3 by a miR-21-dependent proto-oncogenic network underpins SCC in humans. Deletion of Grhl3 in adult epidermis evokes loss of expression of PTEN, a direct GRHL3 target, resulting in aggressive SCC induced by activation of PI3K/AKT/mTOR signaling. Restoration of Pten expression completely abrogates SCC formation. Reduced levels of GRHL3 and PTEN are evident in human skin, and head and neck SCC, associated with increased expression of miR-21, which targets both tumor suppressors. Our data define the GRHL3-PTEN axis as a critical tumor suppressor pathway in SCC.
INTRODUCTION
The mammalian epidermis serves as an impermeable barrier, protecting the organism from the hostile external environment. It is maintained by a self-renewal process in which keratinocytes proliferating in the basal layer detach from the underlying basement membrane, withdraw from the cell cycle, and differentiate while migrating toward the skin surface (Clayton et al., 2007; Fuchs and Raghavan, 2002; Watt, 2001) . Perturbation of the balance between keratinocyte proliferation and differentiation underpins a wide range of skin pathologies. When disrupted during embryogenesis, it results in a markedly thickened epidermis with altered expression of structural proteins leading to a failure of skin barrier formation (Koster, 2009) . In adults it is the central tenet of various disease states, including the epidermal cancers, the most common of all human tumors (Alam and Ratner, 2001; Rogers et al., 2010) .
Although abnormal activation of the sonic hedgehog/patched pathway is critical for the proliferation/differentiation imbalance in basal cell carcinoma (Wetmore, 2003) , the molecular basis
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of squamous cell carcinoma (SCC) has been less well defined (Ridky and Khavari, 2004) . Studies in human tissue models have provided evidence that activation of Ras signaling, in concert with inhibition of NF-kB function, is sufficient for malignant transformation of keratinocytes. In human tumors, Ras activation is most frequently due to mutations in codon 12, 13, or 61 of one of the three Ras genes (Bos, 1989) . However, mutations in Ras isoforms are found in only 22% of SCCs (Khavari and Rinn, 2007) , although some tumors can display increased levels of active Ras-GTP in the absence of a mutation (Dajee et al., 2003) . In the classical skin chemical carcinogenesis model in mice, mutations in codon 61 of the H-Ras gene induced by the topical application of 7, 12-dimethylbenz [a] anthracene (DMBA) predominate (Abel et al., 2009) . Activated Ras stimulates multiple effectors including the Raf/MEK/ERK pathway, the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway, and the guanine nucleotide exchange factors (Repasky et al., 2004) . Each of these has been clearly implicated in the pathogenesis of keratinocyte hyperproliferation and dedifferentiation, and/or overt SCC in mice (Gonzá lez-García et al., 2005; Scholl et al., 2007; Segrelles et al., 2007) , although data from primary human samples are less compelling, or completely lacking.
An alternate mechanism for activation of PI3K/AKT/mTOR signaling in SCC is through loss of expression of the phosphatase and tensin homolog (PTEN) tumor suppressor gene. Previous studies have suggested that activation of H-ras and complete loss of Pten are mutually exclusive in skin carcinomas (Mao et al., 2004) . PTEN acts as the most important negative regulator of the PI3K pathway, converting phosphatidylinositol 3,4,5-triphosphate (PIP 3 ), the product of activated PI3K, to phosphatidylinositol 4,5-biphosphate (PIP 2 ) (Stambolic et al., 1998; Maehama and Dixon, 1998) . Inactivation of PTEN leads to accumulation of PIP 3 , and as a consequence, increased activity of the serine/threonine kinases PDK1 and AKT, which promote cellular survival, cell cycle progression and growth, angiogenesis, and cellular metabolism through phosphorylation of numerous diverse cellular substrates (Manning and Cantley, 2007) . AKT activation also leads to activation of the mTOR kinase complex 1 (mTORC1), resulting in activation of S6K1 and phosphorylation of 4EBP1, and enhanced protein translation through multiple effector pathways. PTEN has been implicated in SCC in both humans and mice (Ming and He, 2009; Suzuki et al., 2003) . Despite this, somatic mutations, gene deletions, and promoter hypermethylation of PTEN have not been detected in human SCC, suggesting that other mechanisms of inactivating the gene may be involved in SCC pathogenesis (Ming and He, 2009) .
Another tumor suppressor of SCC in humans and mice is IkB kinase a (IKKa) (Liu et al., , 2008 Maeda et al., 2007) . Adult mice with a targeted deletion of this gene in keratinocytes develop epidermal hyperproliferation, perturbed expression of differentiation markers, and ultimately, spontaneous SCC (Liu et al., 2008) . Constitutive deletion of IKKa during embryogenesis leads to a thickened and undifferentiated epidermis, with neonates dying of dehydration due to a profound skin barrier defect (Hu et al., 1999; Takeda et al., 1999) . These findings are of considerable interest because they demonstrate that a key regulator of keratinocyte proliferation/differentiation balance during embryonic development can also play a major role as a tumor suppressor in adulthood (Descargues et al., 2008) .
We have previously shown that mice lacking the Grainy headlike 3 (Grhl3) gene exhibit a markedly thickened epidermis, perturbed expression of multiple epidermal differentiation markers, and defective skin barrier formation, with newborn pups dying of dehydration Yu et al., 2006) . Grhl3 is a member of a highly conserved family of transcription factors critical for epidermal development and homeostasis across a wide range of species (Jane et al., 2005; Venkatesan et al., 2003; Wilanowski et al., 2002) . Expression of this gene is largely confined to the surface ectoderm during embryogenesis, and in adulthood occurs in tissues that arise from this embryonic layer, including the skin, and lining of the oral cavity. The antecedent member of this family in Drosophila, grainy head (grh) plays central roles in cuticle formation and repair (Bray and Kafatos, 1991; Mace et al., 2005) . In view of the essential role played by Grhl3 in maintaining the proliferation/differentiation balance in epidermal ontogeny, and the burgeoning links between conserved developmental genes and cancer (Dean, 1998) , we have further investigated the role of Grhl3 in adult skin homeostasis and skin cancer development.
RESULTS

Grhl3 Deletion during Embryogenesis Causes Epidermal Keratinocyte Hyperproliferation
Our initial experiments focused on the proliferative potential of keratinocytes in the Grhl3 null mice. The epidermis in embryonic day (E) 18.5 Grhl3 À/À animals was markedly thickened (Figure 1A) , and expression of the proliferative marker PCNA was expanded compared to wild-type epidermis, with mitotic cells extending into the suprabasal layers ( Figure 1B ). This hyperproliferation was cell intrinsic because keratinocytes cultured from E18.5 Grhl3 À/À embryos grew more rapidly than the wild-type controls ( Figure 1C) , and displayed loss of cell-cell contact inhibition, forming heaped up pseudo-tumors in the culture dish ( Figure 1D ). They also displayed increased colony numbers in soft agar ( Figure 1E ), strengthening the possibility that Grhl3 could play a tumor suppressor role in skin cancer in adult mice. To investigate this, we generated mice carrying a conditionally targetable Grhl3 allele, with loxP sites flanking exons 2 and 4 of the gene (see Figures S1A-S1C available online and Experimental Procedures). Mice homozygous for the floxed alleles (Grhl3 fl/fl ) were healthy and fertile, and when crossed with Grhl3 +/À mice carrying a B6-Cre transgene expressed at the two-cell stage of development, generated Grhl3 D/À /B6-Cre+ mice (where D is the deleted floxed allele) that phenocopied the Grhl3 null animals (Ting et al., 2003 ) (data not shown).
To delete Grhl3 in the skin, we crossed Grhl3 fl/À mice with a line carrying a keratin (K) 14-driven Cre transgene. Although patchy deletion in the epidermis has been reported with this line as early as E13.5 (using a ROSA cross) (Jonkers et al., 2001) , analysis of the epidermis in E18.5 Grhl3 fl/À /K14Cre+ embryos revealed less than 20% deletion ( Figure S1D) , and all E18.5 Grhl3 fl/À /K14Cre+ embryos displayed normal skin barrier formation (data not shown). High levels of deletion (>95%) of the Grhl3 fl allele were only detected after birth (from P1 onward) ( Figure S1D ), and consistent with this, expression of Grhl3 in the deleted skin was markedly reduced ( Figure S1E Figure 2A ). The rapidity of tumor formation was striking; particularly because the background strain of the mutant animals (C57Bl/6) is notoriously resistant to chemical-induced tumor formation (Sundberg et al., 1997) . Total tumor numbers were also markedly higher in the mutant versus wild-type mice ( Figure 2B ), and many of the papillomas progressed on to form SCCs ( Figure 2C) , a rare event in the wild-type mice. The SCCs grew rapidly and were often multiple (Figures 2D), and histologically were poorly differentiated with numerous mitoses ( Figure 2E ). The epidermis adjacent to the tumors was markedly thickened compared to wild-type mice and resembled the epidermis from Grhl3 null embryos (Figure S2, H&E) . Consistent with this, perturbed expression of the terminal differentiation markers filaggrin and involucrin, and the Ks 5, 6, and 10 in the Grhl3-deleted adult skin also mirrored the changes observed in the Grhl3 null embryos ( Figure S2A ) (Yu et al., 2006) . Expression of Grhl3 was markedly reduced in treated skin prior to the onset of tumors, and completely absent in both papillomas and SCCs from the Grhl3 D/À /K14Cre+ mice ( Figure 2F ). Tumors were also observed with high frequency in Grhl3 D/À /K14Cre+ animals, but not wild-type controls (n = 10 in each group) treated with TPA alone ( Figure 2G ; Figure S2B ), suggesting that loss of Grhl3 is sufficient for disease initiation. With aging, 100% of the untreated Grhl3
/K14Cre+ mice developed epidermal hyperplasia and spontaneous tumors that were predominantly squamous papillomas or carcinomas affecting the snout and neck ( Figure 2H ). Identical findings were obtained when mouse mammary tumor virus (MMTV)-Cre transgenic mice were used to delete Grhl3 in keratinocytes (data not shown) (Liu et al., 2008) . These snout and neck tumors in both Grhl3 D/À lines phenocopied changes observed in mice with a keratinocyte-specific deficiency of the tumor suppressor, Pten (Suzuki et al., 2003) .
PTEN Is a Direct Transcriptional Target Gene of GRHL3
The DNA consensus-binding site for human GRHL3 and its Drosophila homolog, grh, has been conserved across 700 million years of evolution . On this basis we predicted that GRHL3 target genes should contain this motif conserved across a wide range of species. Therefore, we interrogated a customized data set of genomic regions located within 10 kb of gene transcriptional start sites that are conserved in placental mammals with the GRHL3 consensus (and highly related sequences), an approach we had successfully employed to identify a key GRHL3 target in wound repair (Caddy et al., 2010) . We identified a highly conserved site in the promoter region of the Pten gene ( Figure 3A ) (Li et al., 1997) , and confirmed specific binding of GRHL3 to this site in vitro in electrophoretic mobility shift assays (EMSA) ( Figure 3B ), and in vivo by chromatin immunoprecipitation (ChIP) ( Figure 3C ). We also demonstrated that transcriptional activation of the Pten promoter by Grhl3 was dependent on the integrity of this site in reporter gene assays ( Figure S3A ). Consistent with Pten being a direct target of GRHL3, expression of the gene was markedly reduced in the skin of Grhl3 null E18.5 embryos at both RNA and protein level ( Figure 3D ). Loss of PTEN leads to accumulation of PIP 3 , and as a consequence, increased activity of the serine/threonine kinases PDK1 and AKT, with resultant activation of mTORC1 (Manning and Cantley, 2007) . This leads to activation of S6K1 and phosphorylation of 4EBP1 and ribosomal protein S6, which provide a robust readout of mTORC1 signaling (Guertin and Sabatini, 2007; Ma and Blenis, 2009 ). Analysis of these downstream effectors of PI3K signaling in epidermis from Grhl3 null embryos revealed increased levels of AKT, PDK1, S6, and 4EBP1, as well as their phosphorylated forms, p-AKT, p-PDK1, p-S6, and p-4EBP1 Figure S3A .) (B) EMSA of recombinant (r) GRHL3 binding to the Pten promoter probe. A 100-fold molar excess of unlabelled cold competitor probes (Pten or Grhl3 consensus) was added in the indicated lanes. The migration of the specific GRHL3/DNA complex is arrowed. (C) ChIP analysis of endogenous GRHL3 on the PTEN promoter. Chromatin from the human keratinocyte line (HaCaT) was immunoprecipitated using antisera to GRHL3, and amplified with PTEN primers. Preimmune sera (IgG) and the muscle-specific MyoD promoter were used as negative controls, and the input chromatin is shown. 
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A Proto-Oncogenic Network in SCC ( Figure 3E ). This increase in abundance and activity of these proteins reflects a high level of mTORC1 signaling (Ma and Blenis, 2009) . The levels of the catalytic p110a isoform and the p85 regulatory subunit of the PI3K protein, which lie upstream of PTEN, were not altered. PTEN levels were markedly reduced in the basal layer of the epidermis, and coincident with this, the levels of p-AKT were increased in this layer, and the adjacent suprabasal layer ( Figure 3F ). The size of the cells in the basal layer was also increased ( Figure S3B ), a feature common to cells from mice lacking Pten (Groszer et al., 2001 ).
To determine whether Grhl3 and Pten interacted epistatically, we intercrossed mice carrying heterozygous deletions of the two ) display increased susceptibility to DMBA/TPA-induced tumors (Mao et al., 2004) , the additional loss of a single Grhl3 allele enhanced both the rapidity of cancer development and the number of mice with multiple aggressive SCCs ( Figure 4B) . Conversely, the restoration of Pten to wild-type status in the Grhl3 +/À /Pten +/+ mice almost completely safeguarded these animals against SCC formation. The susceptibility of the different genotypes to SCC was reflected in their levels of Pten expression ( Figure 4C ). Taken together, these data suggest that Pten is the critical downstream target of Grhl3 for prevention of SCC. To confirm this in a human model, we generated a human keratinocyte cell line (HaCaT) in which the expression of GRHL3 had been knocked down using a specific shRNA containing lentivirus (GRHL3-kd) (Figure 4D ) (Caddy et al., 2010) . A line transduced with a scrambled control (Scr) shRNA served as the control. In keeping with our earlier findings, the level of PTEN was markedly reduced in the GRHL3-kd line compared to control, and p-AKT and p-S6 levels were increased in these cells in both the presence ( Figure 4D ) and absence of serum ( Figure S4 ). This latter result was consistent with the resistance to growth factor and nutrient withdrawal observed with constitutive PI3K activation in tumor cell lines (Kalaany and Sabatini, 2009 ). The GRHL3-kd cells also proliferated more rapidly than the Scr cells ( Figure 4E ). Reintroduction of wild-type PTEN into the GRHL3-kd line restored the inhibition of phosphorylation of AKT and S6 ( Figure 4D) , and led to suppression of cell growth ( Figure 4E ). In contrast, introduction of the C124S phosphatase dead PTEN mutant (Myers et al., 1998) , to equivalent levels to that achieved with the wild-type protein, failed to inhibit AKT and S6 phosphorylation ( Figure 4D ), and also failed to suppress the enhanced proliferation of the GRHL3-kd cells ( Figure 4E ). These findings suggest that Pten is the critical downstream target of GRHL3 in tumorigenesis.
Activation of PI3K/AKT and Repression of Ras/MAPK/ ERK Signaling in Grhl3-Deficient Tumors We next compared PTEN levels and PI3K signaling in unaffected skin, papillomas, and SCCs derived from both wild-type and Grhl3
/K14Cre+ mice ( Figures 5A and 5B ). Cellular proliferation in the SCCs was demonstrated by PCNA staining (Figure S5A) . Loss of GRHL3 was associated with a reduction in PTEN in unaffected skin, and almost complete loss in papillomas and SCCs that was not observed in the wild-type skin or tumors. This was accompanied by increased levels of p-S6 and p-AKT in the tumors from Grhl3 D/À /K14Cre+ mice. Although p-S6 levels were also increased in the tumors from wild-type mice, p-AKT expression was weak, suggesting that the increase in p-S6 was due to other pathways feeding into the mTORC1 pathway below the level of AKT . Of note the increase in p-AKT in the SCC from Grhl3 D/À /K14Cre+ mice compared to wild-type controls was due to both the number of positively staining cells in the tumors and the staining intensity ( Figures S5B and S5C) .
Previous studies have suggested that activation of H-ras and complete loss of Pten are mutually exclusive in skin carcinomas (Mao et al., 2004) . Our findings confirmed this because we detected no mutations in codons 12, 13, or 61 in the H-Ras gene in tumors derived from Grhl3 D/À /K14Cre+ mice, whereas 16% of tumors from the wild-type mice carried mutations in these codons ( Figure 5C ). Similar frequencies of H-Ras mutations have been detected in series of human SCC (Boukamp, 2005) . We also observed an almost complete absence of p-ERK1/2 in tumors from the Grhl3 D/À /K14Cre+ mice despite levels of ERK1/2 that were comparable to unaffected skin, and skin from wild-type controls ( Figures 5D and 5E ). This finding was comparable to the reduction in p-ERK1/2 that we had previously described in the epidermis of Grhl3 null embryos . In contrast the levels of p-ERK1/2 in tumors from wild-type mice were markedly elevated ( Figures 5D and 5E) .
A miR-21-Dependent Proto-Oncogene Network Targets GRHL3 and PTEN To establish the relevance of our mouse findings in the human system, we analyzed the expression of GRHL3 by Q-RT-PCR in 37 consecutive primary human SCCs, and the adjacent nontumor-affected epidermis isolated by laser capture microdissection (LCM). In almost all cases GRHL3 levels were markedly reduced in the tumors compared to the adjacent epidermis, with expression reduced by more than 90% in over half the samples ( Figure 6A) . A coordinate reduction in PTEN expression was also observed in these tumors ( Figure 6A ; Figure S6A ). Interestingly, a similar reduction in GRHL3 and PTEN levels was also observed in SCCs of head and neck origin (HNSCCs) (Figure S6B ), suggesting a common molecular mechanism for cancers of this histological subtype. Sequence analysis of the GRHL3 coding exons and splice donor and acceptor sites failed to detect any mutations in the tumors, and the methylation status of the CpG islands in the GRHL3 promoter was unchanged in tumors compared to normal skin (data not shown).
An alternate mechanism for the reduction in GRHL3 expression in the tumors could be through overexpression of a specific microRNA (miRNA), which have been shown in some contexts to function as oncogenes by targeting tumor suppressors (Hammond, 2006; Esquela-Kerscher and Slack, 2006; Garzon et al., 2010) . To examine this, we interrogated a miRNA array with total RNA derived from two human SCCs with undetectable levels of GRHL3, and their matched normal skin controls ( Figure 6B ). We focused on miRNAs that were predicted to target GRHL3 using the mirWIP database (Hammell et al., 2008) . Of this set, miR-21 exhibited the greatest differential between normal and tumor tissue, and its sequence aligned with nucleotides 414-436 in the GRHL3 3 0 UTR ( Figure 6C ). Interestingly, miR-21 has previously been shown to function as an oncogene by targeting PTEN (Meng et al., 2007) . We examined an additional ten SCCs, and their matched controls, and demonstrated a greater than 6-fold difference in miR-21 expression between the two groups ( Figure 6D ). We confirmed that enforced expression of miR-21 ( Figure S6C ) could inhibit GRHL3 mRNA expression in the human HaCaT cell line ( Figure 6E ), in keeping with recent reports indicating that mRNA destabilization usually comprised the major component of miR-dependent gene repression (Baek et al., 2008; Selbach et al., 2008) . Expression of PTEN mRNA was also reduced in this line, consistent with the effect on GRHL3, and with direct targeting of PTEN by miR-21 ( Figure 6F ). GRHL3 and PTEN protein levels were also markedly reduced in the miR-21 expressing HaCaT cells (Figure 6G) , and this was accompanied by enhanced cell growth ( Figure S6D ). We established that GRHL3 was a direct target of miR-21, using a luciferase reporter linked to the GRHL3 3 0 UTR ( Figure 6H ). Cotransfection of this construct with a miR-21 expression vector into HEK293 cells resulted in a marked reduction in luciferase activity compared to a Scr sequence, and this was reversed when an antagomir of miR-21 (miRZip21) was also transfected. Deletion of the miR-21 binding site in the GRHL3 3 0 UTR completely abrogated its effect ( Figure 6H ), indicating that GRHL3 is a direct target of miR-21.
The miR-21-Dependent Proto-Oncogene Network Is Active in Both Skin and HNSCC To determine whether the miR-21-dependent proto-oncogene network had broader relevance in SCC, we examined expression of miR-21, GRHL3, and PTEN in a range of human SCC cell lines derived from both epidermal (SCC-13), and head and neck (SCC-4, -9, -15, -25, and CAL-27) origins. All SCC lines tested, except SCC-4, exhibited elevated levels of miR-21
A Proto-Oncogenic Network in SCC compared to HaCaT cells, with corresponding reductions in both GRHL3 and PTEN levels ( Figure 7A ). To assess the consequences of inhibition of miR-21 in HNSCC, we utilized the miRZip21 antagomir in the SCC-9 cell line, achieving a substantial reduction in miR-21 levels compared to cells transduced with a Scr control ( Figure 7B ). This resulted in a greater than 10-fold induction of GRHL3 expression at both RNA ( Figure 7C) and protein ( Figure 7D ) level, resulting in increased levels of PTEN, inhibition of PI3/AKT signaling ( Figure 7D ), and marked inhibition of cell proliferation ( Figure 7E ). These finding suggest that activation of the miR-21-dependent proto-oncogene network may be a common molecular mechanism in SCC of different tissue origins, and that targeting of this network may have therapeutic potential. 
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DISCUSSION
Our data define the Grhl3 gene as a potent suppressor of SCC of the skin in mammals, acting through the direct transcriptional regulation of Pten. Supporting this conclusion are phylogenetic, biochemical, and expression data coupled with functional rescue studies in vitro in a human system, and in vivo in the mouse. In addition, clear parallels exist between Grhl3-deficient mice and mice lacking Pten in the adult epidermis, although the phenotype in the latter animals is somewhat variable, and is dependent on the strategy utilized for gene deletion (Suzuki et al., 2003; Yao et al., 2006; Mao et al., 2004) . Our findings also implicate Grhl3 in the pathogenesis of HNSCC in humans, providing possible alternate therapeutic strategies for targeting cancers that are often associated with an extremely poor prognosis. Although PTEN has been thought to be constitutively expressed, and minimally regulated in normal tissues , our findings refute this paradigm in one setting by establishing the pivotal importance of tissue-specific control of Pten expression in suppression of SCC. The integral function of Grhl3 in this process, coupled with its role in maintaining the balance between keratinocyte differentiation and proliferation, defines Grhl3 as a critical innate surveillant to prevent skin cancer. In this regard its function is similar to IKKa, which also induces keratinocyte terminal differentiation and prevents SCC (Liu et al., 2008; Park et al., 2007) . However, in contrast to IKKa-deficient tumors that exhibit EGFR-induced ERK activation, loss of Grhl3 results in exclusive upregulation of PI3K/AKT/mTOR signaling, with a complete loss of p-ERK expression and no change in the levels of p-EGFR ( Figure S3C ). The absence of Ras mutations and the marked downregulation of the MAPK/ERK-signaling pathway in the tumors from Grhl3 D/À /K14Cre+ mice are similar to the findings observed in Pten-deficient mice (Mao et al., 2004) , indicating that in the absence of Pten, this pathway is dispensable for SCC formation. Similar results were also observed in RU486-inducible K14.Cre/ Pten fl/fl mice that coexpress an Ha-Ras transgene, in which TPAmediated tumor progression involved PTEN-associated pathways rather than Ras activation (Yao et al., 2006) .
Although we have now identified several GRHL3 target genes that are involved in the diverse developmental processes regulated by this transcription factor (Caddy et al., 2010; Ting et al., 2005) , the loss of Pten alone appears to be sufficient for the increased susceptibility of the Grhl3-deficient mice to both chemical-induced and spontaneous SCC. This is illustrated by the profound difference in cancer susceptibility between Grhl3 et al., 2010) . Our data in GRHL3-kd keratinocytes also indicate that PTEN is the critical downstream target of GRHL3 in the human system, with wild-type, but not a phosphatase-dead mutant PTEN, able to repress PI3K/AKT/mTOR signaling and inhibit cell hyperproliferation. This is further supported by our studies on the SCC9 cell line, in which miRZip21-induced enhanced expression of GRHL3 leads to upregulation of PTEN levels, suppression of PI3K/AKT signaling, and reduced cell proliferation. The reduced expression of both GRHL3 and PTEN mediated by upregulation of miR-21 in human skin SCC explains the long-standing paradox of loss of PTEN expression in the absence of genetic or epigenetic alterations to the gene (Ming and He, 2009 ). The coordinate targeting of both tumor suppressors by miR-21 provides a classic example of the emerging theme of miRNA-dependent amplification of signaling cascades, which are evident in both normal and cancerous tissues (Inui et al., 2010) . In this setting the synchronous regulation of the pathway inhibitor (PTEN) and its transcriptional regulator (GRHL3) by a solitary miR (miR-21) establishes a proto-oncogenic network involving enhanced PI3K/AKT/mTOR signaling in these tumors. The extension of our findings from skin SCC to HNSCC is in keeping with the common embryonic origins of these tissues, and the expression of Grhl3 in all adult epithelium derived from the developing surface ectoderm. It is also consistent with previous studies identifying GRHL3 as a gene exhibiting reduced expression in primary and metastatic HNSCC (Nguyen et al., 2007; Rickman et al., 2008) , and with the increased expression of miR-21 reported in multiple HNSCC series (Volinia et al., 2006; Avissar et al., 2009; Hui et al., 2010) .
Emerging from our work is an increased rationale for the use of direct inhibitors of PI3K/AKT/mTORC1 signaling and/or antagonists of miR-21 in the treatment of SCC. Recent studies have identified an mTORC1-PI3K-dependent negative feedback loop regulating MAPK/ERK signaling in cancer, with increased p-ERK levels observed in tumors treated with the TORC1 inhibitor RAD001 . It will be of considerable interest to determine whether Grhl3-dependent skin SCCs display activation of MAPK/ERK signaling when treated with TORC1 inhibitors, or alternatively, exhibit true oncogene addiction to constitutively active PI3K/AKT/mTOR signaling. The latter finding may pave the way for novel therapeutic interventions in invasive SCC of the skin. In the context of HNSCC, new treatments have focused on inhibitors of EGFR, although targeting of the PI3K/AKT pathway is also under investigation (Leemans et al., 2011) . As with other cancers, the PTEN expression status may influence response to EGFR inhibitors (Jhawer et al., 2008) , and antagonists of miR-21 may offer benefits as single agents, or in combination with agents such as cetuximab.
EXPERIMENTAL PROCEDURES
Generation of Experimental Animals
All experiments were preapproved by The University of Melbourne Animal Ethics Committee. The generation and genotyping of Grhl3 +/À mice have been described previously (Ting et al., 2003) . The conditional Grhl3 targeting vector was constructed and validated as detailed in the Supplemental Experimental Procedures (Figures S1A-S1C ). Grhl3 +/À mice were crossed with K14Cre+ transgenic mice (Jonkers et al., 2001) , and the resultant animals were crossed with Grhl3 fl/fl mice to provide the Grhl3 Tumor Induction and Skin Barrier Analysis in Mice Tumors were induced in mice through the application of 25 mg DMBA (SigmaAldrich) in acetone to a shaved area on the back followed 1 week later by
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A Proto-Oncogenic Network in SCC twice-weekly application of TPA (7.6 nmol) in 150 ml of acetone for up to 30 weeks. In some experiments TPA was applied without DMBA initiation. Skin barrier analysis was performed as previously described (Hardman et al., 1998) . /K14Cre+ mice were homogenized in TRIzol (Invitrogen) and RNA extracted according to the manufacturer's instructions. Q-RT-PCR was carried out as described previously (Ting et al., 2003) with primer sequences shown in the Supplemental Experimental Procedures. A Student's t test was used to determine statistical difference in expression levels with p values <0.05 considered significant, and results were analyzed using Prism (GraphPad). The error bars in all expression analyses represent the standard error of the mean (SEM).
RNA Preparation and Q-RT-PCR
ChIP and EMSA ChIP was performed as described previously (Wilanowski et al., 2008) , with anti-GRHL3 antibodies (Aviva Systems Biology, San Diego, CA). EMSAs were performed using recombinant mouse GRHL3 protein, and oligonucleotides containing the conserved GRHL3-binding site in the Pten promoter. The DNA consensus-binding site for GRHL3 was used as a cold competitor . Primer and oligonucleotide sequences for the Pten promoter are shown in the Supplemental Experimental Procedures.
Immunoblot Analysis and IHC
Immunoblotting and IHC methodologies and the antibodies employed are detailed in the Supplemental Experimental Procedures. For quantification of IHC, eight images (203) were taken per tumor and the positive p-AKT cells counted. The staining intensity of the tumor was quantified using MetaMorph image analysis software and plotted as percentage of staining intensity of the total area (Hambardzumyan et al., 2008) .
shRNAs and Retroviral Infection
The shRNA target oligonucleotides for Grhl3 and the Scr were cloned into the pSUPER.retro.neo+GFP vector using the BglII and HindIII sites. The target sequences and generation of viruses are detailed as previously described (Caddy et al., 2010) . HaCaT cells were transduced over a 24 hr period, and GFP-positive cells were selected by FACS, and cultured for 8 days, or harvested for preparation of lysates. Knockdown of GRHL3 expression was confirmed by immunoblot using antibodies to GRHL3 and GAPDH. For expression of wild-type PTEN, or the phosphatase dead C124S PTEN mutant in GRHL3-kd cells, the respective cDNAs were cloned into MSCV-DSRed using the BamHI and XhoI sites. PTEN expression was confirmed in DSRed+ cells by immunoblot using PTEN antibody, and GAPDH as a loading control.
LCM
Deidentified surgical specimens of SCC resected from patients (including tumor and adjacent normal tissue) were embedded in OCT medium and stored at À80
C. The sections were stained with HistoGene LCM Frozen Staining Kit just before commencing LCM. The cryosections (8 mm) were microdissected using a VeritasÔ microdissection instrument (Arcturus) according to the standard protocol. Tumor tissues and normal tissues were captured onto CapSure Macro LCM Caps. RNA extraction and amplification were performed according to the manufacturer's instructions. The reagents for staining, RNA extraction, and RNA amplification were obtained from Arcturus. Q-RT-PCR was performed as detailed above. Ethics approvals were obtained from the Victorian Tissue Biobank and the Human Research Ethics Committee of the Royal Melbourne Hospital.
Mutational Analysis of H-ras PCR primers amplifying codons 12, 13, and 61 were designed on the basis of genomic DNA sequences for H-ras. Mutations were detected by sequencing as previously described (Ise et al., 2000) . The mutations were further confirmed by restriction fragment length polymorphism (RFLP) analysis as previously detailed (Jaworski et al., 2005) .
Luciferase Assays
Reporter gene analysis of the Pten promoter is detailed in the Supplemental Experimental Procedures. For analysis of miR-21 regulation of GRHL3, the 3 0 UTR region of human GRHL3 containing the predicted site for miR-21 was subcloned into the pMIR-REPORT luciferase vector (pMIR-GRHL3 0 UTR luciferase) (Applied Biosystems). A mutant construct (Mut21) was generated by deleting 10 bp (419-428) from the miR-21 site in the 3 0 UTR of GRHL3 (pMIR-GRHL3 0 UTR-Mut21 luciferase). Both constructs (0.5 mg) were transfected into HEK293T cells with the pMIR-b-galactosidase vector. After 15 hr, the miR-21 precursor construct was coinfected with and without the lentivector-based antagomir to miR-21 ''miRZip-21'' (System Biosciences). Firefly luciferase was measured 48 hr after transfection/infection using the Dual-Light Chemiluminescent Reporter Gene Assay System (Applied Biosystems), as per the manufacturer's instructions, and normalized to b-galactosidase activity to control for differences in transfection efficiency.
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